SE9703414D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE9703414D0
SE9703414D0 SE9703414A SE9703414A SE9703414D0 SE 9703414 D0 SE9703414 D0 SE 9703414D0 SE 9703414 A SE9703414 A SE 9703414A SE 9703414 A SE9703414 A SE 9703414A SE 9703414 D0 SE9703414 D0 SE 9703414D0
Authority
SE
Sweden
Prior art keywords
pct
sec
new compounds
date
pub
Prior art date
Application number
SE9703414A
Other languages
English (en)
Swedish (sv)
Inventor
Nils-Aake Bergman
Ambra Thomas D
Garry Pilling
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9703414A priority Critical patent/SE9703414D0/xx
Publication of SE9703414D0 publication Critical patent/SE9703414D0/xx
Priority to ZA988353A priority patent/ZA988353B/xx
Priority to US09/171,779 priority patent/US6127414A/en
Priority to AT98945708T priority patent/ATE228500T1/de
Priority to PCT/SE1998/001686 priority patent/WO1999015498A1/en
Priority to EEP200000171A priority patent/EE200000171A/xx
Priority to TR2000/00785T priority patent/TR200000785T2/xx
Priority to PL98339617A priority patent/PL339617A1/xx
Priority to CA002303528A priority patent/CA2303528A1/en
Priority to BR9812492-7A priority patent/BR9812492A/pt
Priority to AU92889/98A priority patent/AU9288998A/en
Priority to CN98811336A priority patent/CN1279666A/zh
Priority to JP2000512808A priority patent/JP2001517651A/ja
Priority to DE69809782T priority patent/DE69809782T2/de
Priority to IL13499398A priority patent/IL134993A0/xx
Priority to SK360-2000A priority patent/SK3602000A3/sk
Priority to EP98945708A priority patent/EP1017672B1/en
Priority to KR1020007003029A priority patent/KR20010024220A/ko
Priority to ARP980104740A priority patent/AR017138A1/es
Priority to IS5410A priority patent/IS5410A/is
Priority to NO20001483A priority patent/NO20001483L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9703414A 1997-09-23 1997-09-23 New compounds SE9703414D0 (sv)

Priority Applications (21)

Application Number Priority Date Filing Date Title
SE9703414A SE9703414D0 (sv) 1997-09-23 1997-09-23 New compounds
ZA988353A ZA988353B (en) 1997-09-23 1998-09-11 New NPY antagonists
KR1020007003029A KR20010024220A (ko) 1997-09-23 1998-09-21 신규한 ｎｐｙ 길항제
CA002303528A CA2303528A1 (en) 1997-09-23 1998-09-21 New npy antagonists
CN98811336A CN1279666A (zh) 1997-09-23 1998-09-21 新的npy拮抗剂
PCT/SE1998/001686 WO1999015498A1 (en) 1997-09-23 1998-09-21 New npy antagonists
EEP200000171A EE200000171A (et) 1997-09-23 1998-09-21 Uued NPY antagonistid
TR2000/00785T TR200000785T2 (tr) 1997-09-23 1998-09-21 Yeni NPY antagonistleri.
PL98339617A PL339617A1 (en) 1997-09-23 1998-09-21 Novel antagonists of neuropeptide y
US09/171,779 US6127414A (en) 1997-09-23 1998-09-21 NPY antagonists
BR9812492-7A BR9812492A (pt) 1997-09-23 1998-09-21 Composto, uso do mesmo, formulação farmacêutica, e, processos para o tratamento de uma doença cardiovascular, para o tratamento de uma vasoconstrição, e para a preparação de compostos
AU92889/98A AU9288998A (en) 1997-09-23 1998-09-21 New npy antagonists
AT98945708T ATE228500T1 (de) 1997-09-23 1998-09-21 Npy antagonisten
JP2000512808A JP2001517651A (ja) 1997-09-23 1998-09-21 新しいｎｐｙ拮抗剤
DE69809782T DE69809782T2 (de) 1997-09-23 1998-09-21 Npy antagonisten
IL13499398A IL134993A0 (en) 1997-09-23 1998-09-21 New npy antagonists
SK360-2000A SK3602000A3 (en) 1997-09-23 1998-09-21 New npy antagonists
EP98945708A EP1017672B1 (en) 1997-09-23 1998-09-21 New npy antagonists
ARP980104740A AR017138A1 (es) 1997-09-23 1998-09-22 Compuestos antagonistas del neuropeptido y, formulaciones farmaceuticas que los incluyen, usos farmaceuticos de tales compuestos y procedimientos parala preparacion de los mismos.
IS5410A IS5410A (is) 1997-09-23 2000-03-20 Ný mótlyf taugapeptíðs Y (NPY)
NO20001483A NO20001483L (no) 1997-09-23 2000-03-22 Nye NPY-agonister

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703414A SE9703414D0 (sv) 1997-09-23 1997-09-23 New compounds

Publications (1)

Publication Number Publication Date
SE9703414D0 true SE9703414D0 (sv) 1997-09-23

Family

ID=20408331

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9703414A SE9703414D0 (sv) 1997-09-23 1997-09-23 New compounds

Country Status (21)

Country Link
US (1) US6127414A (sk)
EP (1) EP1017672B1 (sk)
JP (1) JP2001517651A (sk)
KR (1) KR20010024220A (sk)
CN (1) CN1279666A (sk)
AR (1) AR017138A1 (sk)
AT (1) ATE228500T1 (sk)
AU (1) AU9288998A (sk)
BR (1) BR9812492A (sk)
CA (1) CA2303528A1 (sk)
DE (1) DE69809782T2 (sk)
EE (1) EE200000171A (sk)
IL (1) IL134993A0 (sk)
IS (1) IS5410A (sk)
NO (1) NO20001483L (sk)
PL (1) PL339617A1 (sk)
SE (1) SE9703414D0 (sk)
SK (1) SK3602000A3 (sk)
TR (1) TR200000785T2 (sk)
WO (1) WO1999015498A1 (sk)
ZA (1) ZA988353B (sk)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802075D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
US6312898B1 (en) * 1999-04-15 2001-11-06 Hormos Medical Oy, Ltd. Diagnosis of a person's risk of developing atherosclerosis or diabetic retinopathy based on leucine 7 to proline 7 polymorphism in the prepro-neuropeptide Y gene
SE9902596D0 (sv) * 1999-07-06 1999-07-06 Astra Ab Pharmaceutically active compounds
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
SE0101328D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Therapeutic treatment
EP1388537A1 (en) * 2001-05-15 2004-02-11 Taisho Pharmaceutical Co., Ltd Arginine derivatives
US7371871B2 (en) 2003-05-05 2008-05-13 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2338490A3 (en) 2003-11-03 2012-06-06 Probiodrug AG Combinations useful for the treatment of neuronal disorders
FR2864830B1 (fr) * 2004-01-06 2006-03-10 Centre Nat Rech Scient Procede de synthese sur support solide de composes peptidiques, notamment de composes peptidiques comportant un residu arginine
EP1713780B1 (en) 2004-02-05 2012-01-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
FR2884516B1 (fr) * 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
KR100689499B1 (ko) * 2005-10-26 2007-03-02 삼성전자주식회사 휴대단말기에서 키 설정 정보 디스플레이 방법
WO2007064272A1 (en) * 2005-11-29 2007-06-07 Astrazeneca Ab Benzhydryl amide derivatives as cannabinoid receptor antagonists or inverse agonists
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
ES2481823T3 (es) 2010-03-10 2014-07-31 Probiodrug Ag Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5)
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5873821A (en) * 1992-05-18 1999-02-23 Non-Invasive Technology, Inc. Lateralization spectrophotometer
DE4326465A1 (de) * 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19544687A1 (de) * 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19544686A1 (de) * 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1997025041A1 (en) * 1996-01-09 1997-07-17 Eli Lilly And Company Benzimidzolyl neuropeptide y receptor antagonists
JP4106711B2 (ja) * 1996-03-21 2008-06-25 萬有製薬株式会社 アミノピリジン誘導体
AU3295297A (en) * 1996-06-04 1998-01-05 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5)
CA2260982A1 (en) * 1996-07-23 1998-01-29 Neurogen Corporation Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands
EP0918761B1 (en) * 1996-07-23 2003-05-02 Neurogen Corporation Certain amido- and amino-substituted benzylamine derivatives; a new class of neuropeptite y1 specific ligands
JP2000515150A (ja) * 1996-07-23 2000-11-14 ニューロジェン・コーポレーション 置換ベンジルアミン誘導体：新規な種類の神経ペプチドｙ１特異的リガンド
US6849733B1 (en) * 1996-08-23 2005-02-01 Agouron Pharmaceuticals, Inc. Neuropeptide-Y ligands
EP0955293B1 (en) * 1996-12-03 2003-03-19 Banyu Pharmaceutical Co., Ltd. Urea derivatives
WO1998025907A1 (fr) * 1996-12-12 1998-06-18 Banyu Pharmaceutical Co., Ltd. Derives de pyrazole
CA2274593A1 (en) * 1996-12-13 1998-06-18 Banyu Pharmaceutical Co., Ltd. Novel aminopyrazole derivatives
CA2274594C (en) * 1996-12-16 2006-10-10 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
CA2277965A1 (en) * 1997-02-04 1998-08-06 Marc A. Bruce Dihydropyrimidone derivatives as npy antagonists
AU6267198A (en) * 1997-02-14 1998-09-08 Bayer Corporation Amides as npy5 receptor antagonists
JP2002241368A (ja) * 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
WO1998040356A1 (fr) * 1997-03-12 1998-09-17 Banyu Pharmaceutical Co., Ltd. Medicaments contenant des derives d'aminopyridine comme ingredient actif
US5889016A (en) * 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists

Also Published As

Publication number Publication date
IL134993A0 (en) 2001-05-20
EP1017672A1 (en) 2000-07-12
ZA988353B (en) 1999-03-23
US6127414A (en) 2000-10-03
SK3602000A3 (en) 2001-01-18
EP1017672B1 (en) 2002-11-27
KR20010024220A (ko) 2001-03-26
DE69809782T2 (de) 2003-07-17
WO1999015498A1 (en) 1999-04-01
CN1279666A (zh) 2001-01-10
NO20001483L (no) 2000-05-23
BR9812492A (pt) 2000-09-26
PL339617A1 (en) 2001-01-02
IS5410A (is) 2000-03-20
NO20001483D0 (no) 2000-03-22
JP2001517651A (ja) 2001-10-09
DE69809782D1 (de) 2003-01-09
CA2303528A1 (en) 1999-04-01
TR200000785T2 (tr) 2000-09-21
ATE228500T1 (de) 2002-12-15
AU9288998A (en) 1999-04-12
AR017138A1 (es) 2001-08-22
EE200000171A (et) 2001-04-16

Similar Documents

Publication Publication Date Title
SE9703414D0 (sv) New compounds
PT1000035E (pt) 6-fenilfenantridinas substituidas
BR9502708A (pt) Compostos bem como composiçao farmaceutica comprendendo os mesmos
YU29503A (sh) Novi antiholinergici koji se mogu primeniti kao lekovi, kao i postupak za njihovo dobijanje
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
MX9700430A (es) El uso de compuestos heterociclicos.
BR9707233A (pt) Fenantridinas
TR199901653T2 (xx) Fitalazinonlar.
DE59509846D1 (de) [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE
NZ516599A (en) 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
DE60045508D1 (de) Dalda-analoge und ihre verwendung
DE59510370D1 (de) [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE
FR2712591B1 (fr) Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique.
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
BG105710A (en) 5ht1 antagonists for antidepressant therapy
CO4410330A1 (es) Nuevos derivados de bencimidazol farmacologicamente activos y sus sales de adicion acida
ATE242236T1 (de) N-substituierte 3-azabicyclo(3.2.0)heptan- derivate als neuroleptika
ATE213731T1 (de) Chinoxalinderivate und ihre therapeutische verwendbarkeit
ES2094545T3 (es) Derivados n-substituidos del 3-azabiciclo(3.2.0)heptano, como neurolepticos etc..
HUP0100781A2 (hu) A jóindulatú prosztata hiperplázia kezelésére alkalmas szubsztituált piridino aril piperazin-származékok és a vegyületeket tartalmazó gyógyszerkészítmények
SE9902387D0 (sv) New pharmaceutically active compounds
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
TR200100475T2 (tr) N-İkameli azabisikloheptan türevlerinin üretimleri ve kullanımları.
SE9902596D0 (sv) Pharmaceutically active compounds
DE69403896D1 (de) 4-amino-2-(hetero)aryl-butanamide verwenbar als 5-ht1a-antagonisten